November 30
PolyActiva Chief Strategy Officer Vanessa Waddell on Raising, Rejection, and the Road Ahead
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectCallaghan Innovation is the New Zealand government’s innovation agency, helping businesses succeed through technology. We act as a gateway to innovation in New Zealand by connecting the rest of the world to Kiwi companies, research institutes, incubators, universities and commercialisation offices.
ViewThe Hunter Medical Research Institute (HMRI) is NSW’s second largest medical research institute. Its pioneering partnership with the University of Newcastle and Hunter New England Local Health District delivers key translational research outcomes and technology closely aligned to community health needs. More than 1400 clinical and biomedical researchers and support staff are employed across seven HMRI Research Programs, striving to prevent, cure and treat a diverse range of serious illnesses.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn morePolyActiva Chief Strategy Officer Vanessa Waddell on Raising, Rejection, and the Road Ahead
Read moreScience: The World’s Shared Language That Carried One Founder Across Continents
Read moreENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Clinical Studies of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Read moreBioMedTech Incubator Program Delivered by Brandon BioCatalyst’s CUREator and CSIRO Opens New Funding Round
Read more